Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies
AbstractCancer cells display enhanced growth rates and a resistance to apoptosis. The ability of cancer cells to evade homeostasis and proliferate uncontrollably while avoiding programmed cell death/apoptosis is acquired through mutations to key signaling molecules, which regulate pathways involved in cell proliferation and survival and these mutations allow them to develop resistance to many chemotherapeutic agents, highlighting the need for development of new potent anti-cancer agents. Metformin has long been used as a treatment for type 2 diabetes and has recently attracted attention as a potential agent to be used in the treatment of cancer. The present review summarizes the existing in vitro and in vivo animal studies focusing on the anti-lung cancer effects of metformin and its effects on key proliferative and anti-apoptotic signaling pathways. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Yousef, M.; Tsiani, E. Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies. Cancers 2017, 9, 45.
Yousef M, Tsiani E. Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies. Cancers. 2017; 9(5):45.Chicago/Turabian Style
Yousef, Michael; Tsiani, Evangelia. 2017. "Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies." Cancers 9, no. 5: 45.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.